The preclinical and phase 1 development of the novel oral cathepsin C inhibitor BI 1291583

James D. Chalmers (Lead / Corresponding author), Philipp Badorrek, Claudia Diefenbach, Harald Kögler, Wiebke Sauter, Stefan Kreideweiss, Jens M. Hohlfeld

    Research output: Contribution to journalLetterpeer-review

    5 Downloads (Pure)

    Abstract

    Preclinical and phase 1 study results indicate that BI 1291583 is a reversible, highly potent and highly selective CatC inhibitor that markedly inhibits active NSP production in a dose-dependent manner, supporting phase 2 trials in bronchiectasis patients https://bit.ly/47PZ8E5.

    Original languageEnglish
    Article number00725
    Number of pages5
    JournalERJ Open Research
    Volume10
    Issue number2
    Early online date25 Jan 2024
    DOIs
    Publication statusPublished - 1 Mar 2024

    Fingerprint

    Dive into the research topics of 'The preclinical and phase 1 development of the novel oral cathepsin C inhibitor BI 1291583'. Together they form a unique fingerprint.

    Cite this